TSVT 4.99 2seventy bio, Inc.
| Range: | 1.535-6.4 | Vol Avg: | 315378 | Last Div: | 0 | Changes: | 0.01 |
| Beta: | 1.78 | Cap: | 0.26B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Nov 03 2021 | Empoloyees: | 274 | ||
| CUSIP: | 901384107 | CIK: | 0001860782 | ISIN: | US9013841070 | Country: | US |
| CEO: | Mr. William D. Baird III, M.B.A. | Website: | https://www.2seventybio.com | ||||
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Stock Details
TSVT 2
Goldman Sachs Downgrades 2Seventy Bio Inc. (TSVT) to Sell
Salveen Richter·Thu Jun 06 2024
Goldman Sachs
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow